![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260922_Singapore_CAR_T_Technology_and_Modalities-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Academic Consortium (Singapore)<\/p>\n Event Type<\/strong><\/p>\n Peer-Reviewed Clinical Data<\/p>\n Modality<\/strong><\/p>\n Dual-Antigen CAR-T Cell Therapy<\/p>\n Asset<\/strong><\/p>\n CART2219.1 (LTG2737)<\/p>\n Target<\/strong><\/p>\n CD22 \/ CD19<\/p>\n Disease Area<\/strong><\/p>\n B-Cell Acute Lymphoblastic Leukemia<\/p>\n A peer reviewed Blood Cancer Discovery study reported that all 11 adults and children with relapsed or refractory B cell acute lymphoblastic leukemia achieved complete remission by Day 28 after CART2219.1, and 91 percent were minimal residual disease negative. At 34 months median follow up, 12 month overall survival was 82 percent and leukemia free survival 64 percent without consolidative transplant. The uncontrolled cohort is too small to establish comparative efficacy.<\/p>\n CART2219.1, also called LTG2737, links human derived anti CD22 and anti CD19 binding domains to a CD8 hinge and transmembrane region with 4 1BB and CD3 zeta signaling. The tandem design aims to reduce single antigen escape after CD19 directed therapy. One relapse involved de novo CD19 escape, showing that dual targeting does not eliminate evolutionary risk.<\/p>\n Reported immune effector toxicities included cytokine release syndrome, hematotoxicity and an HLH like syndrome. Exploratory multiomic analyses associated durability with higher CD22 density, a preinfusion CD4 memory program containing IL7R, LEF1, BACH2 and TCF7, postinfusion NK like effector expansion and maintenance of a central memory pool.<\/p>\n Interpretation one is that tandem CD22 and CD19 recognition can produce durable transplant free remissions across pediatric and adult B ALL. The long follow up and universal early remission support activity. Against this, 11 selected participants provide wide survival intervals, no comparator and limited ability to characterize rare severe toxicity.<\/p>\n Interpretation two is that the biomarker findings can guide product selection or manufacturing. The identified memory and antigen density features are biologically coherent, but they are post hoc and high dimensional relative to cohort size. External prospective validation is required before using them for patient or lot decisions.<\/p>\n Upgrade evidence includes multicenter replication, longer event free survival, standardized toxicity reporting and prospective confirmation of antigen density and T cell state biomarkers. Relapse through antigen escape, limited persistence or manufacturing inconsistency would narrow the advantage.<\/p>\n B ALL relapse after CD19 CAR T can arise through loss or alteration of CD19 and poor T cell persistence. CD22 is a complementary B lineage antigen. Tandem CARs place two recognition domains in one receptor, potentially requiring either antigen for activation, but geometry, antigen density, exhaustion and manufacturing state remain major determinants of activity.<\/p>\n This is a positive hematology and cell therapy signal because the clinical follow up and mechanistic profiling extend beyond a transient response report. The study does not prove superiority to other dual CAR designs or establish broad safety. Its strongest platform contribution may be the linked antigen and cell state hypotheses, provided they replicate prospectively.<\/p>\n Signal Importance: 4 of 5. Signal Direction: positive. Confidence in Facts: high because the report is peer reviewed and includes defined follow up. Confidence in Interpretation: moderate low because the cohort is very small and nonrandomized.<\/p>\n","protected":false},"excerpt":{"rendered":" A peer reviewed Blood Cancer Discovery study reported that all 11 adults and children with relapsed or refractory B cell acute lymphoblastic leukemia achieved complete remission by Day 28 after CART2219.1, and 91 percent…<\/p>\n","protected":false},"author":1,"featured_media":3379,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,4],"tags":[202,847,254],"class_list":["post-3369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-technology-modalities","tag-b-cell-acute-lymphoblastic-leukemia","tag-car-t-therapy","tag-cell-therapy"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3369"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3369\/revisions"}],"predecessor-version":[{"id":3395,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3369\/revisions\/3395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3379"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n